Overview: Rickettsia Antibody Panel TestIntroduction: The Rickettsia Antibody Panel Test detects Rickettsia antibodies to diagnose rickettsial infections, causing fever or rash. Following 2023 IDSA guidelines, it uses immunoassays for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected rickettsial diseases like spotted fever.
Other Names: Rickettsia Ab Assay, Rickettsial Infection Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: Rickettsia antibody testing began in the 1940s with tick-borne disease research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Rickettsia antibodies to diagnose rickettsial infections, guides treatment, and evaluates patients with fever or rash.
Test Parameters: 1. Rickettsia Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of fever, rash, or tick exposure.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, rash, or history of tick exposure. Include current medications, especially doxycycline.
Consent: Written consent required, detailing the tests purpose, rickettsial infection implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect Rickettsia IgG and IgM antibodies. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for rickettsial infection diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or early testing can affect results. Cross-reactivity with other infections may reduce specificity.
Clinical Significance: Positive IgM indicates acute rickettsial infection, guiding doxycycline therapy. Positive IgG suggests past exposure, requiring clinical correlation.
Specialist Consultation: Consult an infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: Rickettsia PCR, blood cultures, or skin biopsy to confirm rickettsial infection diagnosis.
Test Limitations: Non-specific for certain rickettsial species; clinical correlation is needed. Sample quality affects sensitivity.
References: IDSA Rickettsial Guidelines, 2023; Clinical Infectious Diseases, Biggs HM, 2022.
